Diclofenac Sodium

證據等級: L5

預測適應症: 0 個

Diclofenac Sodium: Drug Repurposing Evaluation — Awaiting TxGNN Prediction

One-Sentence Summary

Diclofenac sodium is a widely used non-steroidal anti-inflammatory drug (NSAID), commonly prescribed for pain and inflammatory conditions. The TxGNN model has not yet generated predicted new indications for this drug. The evidence pack currently contains significant data gaps that must be resolved before a repurposing analysis can proceed.

Quick Overview

Item	Content
Original Indication	Pain and inflammatory conditions (NSAID — details pending from licence data)
Predicted New Indication	— None (TxGNN prediction not yet available)
TxGNN Prediction Score	N/A
Evidence Level	L5 — No prediction or supporting studies available
Malaysia Market Status	✓ Marketed
Number of Registrations	68
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, no TxGNN prediction has been generated for Diclofenac Sodium, so a mechanistic plausibility assessment cannot be performed at this stage.

Diclofenac sodium is a well-established NSAID that works primarily by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This mechanism underlies its anti-inflammatory, analgesic, and antipyretic effects. It is one of the most widely prescribed NSAIDs globally, with 68 registered products in the Malaysian market, reflecting its broad clinical utility across multiple dosage forms and indications.

Once the TxGNN model generates candidate indications, the COX-inhibition mechanism — along with emerging evidence for anti-inflammatory pathways in conditions such as neurodegeneration, certain cancers, and cardiovascular remodelling — could provide a plausible biological rationale for repurposing. However, this analysis is contingent on completing the data gaps identified below.

Clinical Trial Evidence

Currently no predicted indication is available; therefore, no targeted clinical trial search has been performed.

Literature Evidence

Currently no predicted indication is available; therefore, no targeted literature search has been performed.

Malaysia Market Information

68 registered products were identified via the NPRA database query (2026-03-27). However, detailed licence-level information (authorisation numbers, product names, dosage forms, and approved indication text) was not populated in the evidence pack.

Action Required: Re-query the NPRA database to retrieve full licence details for all 68 registrations and populate the licenses array.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug–drug interaction data were not available in the current evidence pack.

Known general NSAID class concerns (for reference only — not sourced from this evidence pack):

Gastrointestinal bleeding and ulceration risk
Cardiovascular thrombotic events (especially with prolonged use)
Renal impairment
Hypersensitivity reactions (including aspirin-sensitive asthma)

Data Gaps Requiring Resolution

The following blocking and high-severity gaps were identified:

ID	Category	Item	Severity	Impact	Remediation
DG001	Drug Level	TFDA Package Insert Warnings / Contraindications	Blocking	Cannot enter S1 safety preliminary assessment	Download and parse package insert PDF from TFDA website
DG002	Drug Level	Mechanism of Action (MOA)	High	Affects mechanistic relevance analysis	Query DrugBank API (DrugBank ID not yet mapped)
—	Drug Level	DrugBank ID	High	Required for MOA, DDI, and toxicity data retrieval	Map “DICLOFENAC SODIUM” → DrugBank (likely DB00586)
—	Drug Level	Licence details (68 records)	Medium	Cannot display approved indications or dosage forms	Re-query NPRA with full field extraction
—	Prediction	TxGNN predicted indications	Blocking	No repurposing candidates to evaluate	Run TxGNN KG + DL prediction pipeline

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence pack is substantially incomplete — no TxGNN prediction has been generated, the DrugBank ID is unmapped, and all safety fields remain empty. A meaningful repurposing evaluation cannot be conducted until these foundational data gaps are resolved.

To proceed, the following is needed:

Map DrugBank ID — Diclofenac sodium is expected to correspond to DB00586; confirm and populate drugbank_id
Run TxGNN prediction pipeline — Execute both KG and DL prediction methods to generate candidate indications
Retrieve NPRA licence details — Re-query to populate authorisation numbers, product names, dosage forms, and approved indication text for the 68 registrations
Obtain package insert data — Download and parse the package insert PDF to extract warnings, contraindications, and DDI information (DG001 — Blocking)
Query DrugBank for MOA — Once DrugBank ID is confirmed, retrieve mechanism of action, pharmacodynamics, and toxicity data (DG002)
Re-generate evidence pack — After resolving the above gaps, regenerate the evidence pack and re-run this evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.